08:13:56 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-06-03 Bokslutskommuniké 2025
2025-03-03 Kvartalsrapport 2025-Q3
2024-12-04 Kvartalsrapport 2025-Q2
2024-09-26 X-dag ordinarie utdelning INTEG B 0.00 SEK
2024-09-25 Årsstämma 2025
2024-08-29 Kvartalsrapport 2025-Q1
2024-05-30 Bokslutskommuniké 2024
2024-02-29 Kvartalsrapport 2024-Q3
2023-12-04 Kvartalsrapport 2024-Q2
2023-10-04 X-dag ordinarie utdelning INTEG B 0.00 SEK
2023-09-27 Årsstämma 2024
2023-08-31 Kvartalsrapport 2024-Q1
2023-06-08 Bokslutskommuniké 2023
2023-03-01 Kvartalsrapport 2023-Q3
2022-12-01 Kvartalsrapport 2023-Q2
2022-10-03 X-dag ordinarie utdelning INTEG B 0.00 SEK
2022-09-28 Årsstämma 2023
2022-08-31 Kvartalsrapport 2023-Q1
2022-06-10 Bokslutskommuniké 2022
2022-03-02 Kvartalsrapport 2022-Q3
2021-12-02 Kvartalsrapport 2022-Q2
2021-09-09 X-dag ordinarie utdelning INTEG B 0.00 SEK
2021-09-02 Kvartalsrapport 2022-Q1
2021-05-31 Bokslutskommuniké 2021
2021-03-03 Kvartalsrapport 2021-Q3
2020-12-02 Kvartalsrapport 2021-Q2
2020-09-30 Årsstämma 2021
2020-09-09 X-dag ordinarie utdelning INTEG B 0.00 SEK
2020-08-24 Kvartalsrapport 2021-Q1
2020-06-08 Bokslutskommuniké 2020
2020-04-20 Extra Bolagsstämma 2020
2020-03-02 Kvartalsrapport 2020-Q3
2019-12-02 Kvartalsrapport 2020-Q2
2019-09-30 Årsstämma 2020
2019-09-25 X-dag ordinarie utdelning INTEG B 0.00 SEK
2019-09-02 Kvartalsrapport 2020-Q1
2019-06-10 Bokslutskommuniké 2019
2019-03-04 Kvartalsrapport 2019-Q3
2018-12-17 Kvartalsrapport 2019-Q2
2018-09-25 X-dag ordinarie utdelning INTEG B 0.00 SEK
2018-09-24 Årsstämma 2019
2018-09-24 Kvartalsrapport 2019-Q1
2018-06-25 Bokslutskommuniké 2018
2018-03-26 Kvartalsrapport 2018-Q3
2017-12-18 Kvartalsrapport 2018-Q2
2017-09-25 Årsstämma 2018
2017-09-25 Kvartalsrapport 2018-Q1
2017-06-30 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Integrum är verksamt inom medicinteknik. Idag utvecklar bolaget system för skelettförankrade proteser baserat på det framtagna OPRA-implantatsystemet, som senare vidaresäljs till sjukhus världen över. Implantatet sätts på patientens ben med hjälp utav titanskruvar och antas förbättra livet för en stor del patienter med amputation. Bolaget grundades 1998 och har sitt huvudkontor i Mölndal.
2023-04-28 16:39:32

Mölndal, Sweden, April 27[th], 2023 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company has received a patent approval in Australia describing components and design features of the OPRA™ Implant System. The patent period extends until 2037.

Integrum develops the OPRA™ Implant System, a revolutionary implant technology based on the company's deep expertise and innovations in osseointegration, that help amputees regain normal mobility and quality of life.

The current patent includes claims covering the entire system, including the anchoring solution for attaching a prosthesis to the human body as well as the abutment and the abutment screw. These claims extend beyond transfemoral applications, which currently make up most treatment cases, to include treatment in other types of long bone prosthetic applications, such as the upper arm or lower leg.

Further, the claims cover design features for the connection between the abutment and the fixture, allowing a pathway for the communication of physical and biophysical signals between the inside and outside of the human body. Such design aspects are of vital importance to, for example, the e-OPRA™ Implant System - Integrum's state-of-the-art mind-controlled robotic prosthesis.

The patent grants Integrum exclusivity to OPRA™ Implant System from November 7[th], 2017, until 2037 and is vital to the company's commercial success in the Australian market.

"We are very happy to have expanded our reach to Australia with our innovative state-of-the-art products within osseointegration. The next step will be to further implement OPRA™ Implant System as the new standard of care in amputation treatment, and the long-lasting and broad protection the new patent offers will be a key factor in that process," comments Rickard Brånemark, CEO of Integrum.